Teva has agreed to pay a whopping $1.2 billion to settle a US lawsuit claiming its subsidiary Cephalon paid to hold up generic competition to its narcolepsy therapy Provigil. In a statement ...

Cephalon and Ception Therapeutics have entered into an agreement that provides Cephalon with an option to purchase all outstanding capital stock of Ception. Ception's lead drug is reslizumab ...